Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay

AIDS Research and Human Retroviruses

Volumn 12, Issue 14, 1996, Pages 1319-1328

  Mascola, John R ^a,b   Louder, Mark K ^c   Surman, Sonja R ^c   Vancott, Thomas C ^c   Yu, Xiao Fang ^d   Bradac, James ^e   Porter, Kevin R ^b   Nelson, Kenrad E ^d   Girard, Marc ^f   McNeil, John G ^a   McCutchan, Francine E ^c   Birx, Deborah L ^a   Burke, Donald S ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b NAVAL MEDICAL RESEARCH INSTITUTE   (United States)

^c HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE IMMUNIZATION; ANTIBODY DETECTION; ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION SENSITIVITY; PASSIVE IMMUNIZATION; PHYLOGENY; PRIORITY JOURNAL; SEROTYPING; STRAIN DIFFERENCE; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION;

EID: 0029813738     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.1319     Document Type: Article

References (43)

1. Myers G, Korber B, Wain-Hobson S, Jeang K-T, Henderson LE, Pavlakis GN: Human retroviruses and AIDS. Los Alamos National Laboratory, Los Alamos, New Mexico, 1994.
2. Louwagie J, McCutchan FE, Peeters M, Brennan TP, Sanders-Buell E, Eddy GA, van der Groen G, Fransen K, Gershy-Damet G-M, Deleys R, Burke DS: Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. AIDS 1993;7:769-780.
3. Louwagie J, Janssens W, Mascola J, Heyndrickx L, Hegerich P, van der Groen G, McCutchan FE, Burke DS: Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin. J Virol 1995;69:263-271.
4. Gürtler LG, Hauser PH, Eberle J, Von Brunn A, Knapp S, Zekeng L, Tsague JM, Kaptue L: A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J Virol 1994;68:1581-1585.
5. Janssens W, Heyndrickx L, Fransen K, Motte J, Peeters M, Nkengasong JN, Ndumbe PM, Delaporte E, Perret J-L, Atende C, Piot P, van der Groen G: Genetic and phylogenetic analysis of env subtypes G and H in Central Africa. AIDS Res Hum Retroviruses 1994;10:877-879.
6. Weiss RA, Clapham PR, Cheingsong-Popov R, Dalgleish AG, Carne CA, Weller IV, Tedder RS: Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature (London) 1985;316:69-72.
7. Cheng-Mayer C, Homsy J, Evans LA, Levy JA: Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. Proc Natl Acad Sci USA 1988;85:2815-2819.
8. Katzenstein DA, Vujcic LK, Latif A, Boulos R, Halsey NA, Quinn TC, Rastogi SC, Quinnan GV: Human immunodeficiency virus neutralizing antibodies in sera from North Americans and Africans. J Acquir Immune Defic Syndr 1993;3:810-816.
9. Ichimura H, Kliks SC, Visrutaratna S, Ou C-Y, Kalish ML, Levy JA: Biological, serological, and genetic characterization of HIV-1 subtype E isolates from northern Thailand. AIDS Res Hum Retroviruses 1994;10:263-269.
10. Cheingsong-Popov R, Callow D, Beddows S, Shaunak S, Wasi C, Kaleebu P, Gilks C, Petrascu IV, Garaev MM, Watts DM, Constantine NT, Weber JN: Geographic diversity of human immunodeficiency virus type 1: Serologic reactivity to env epitopes and relationship to neutralization. J Infect Dis 1992;165:256-261.
11. Mascola JR, Louwagie J, McCutchan FE, Fischer CL, Hegerich PA, Wagner KF, Fowler AK, McNeil JG, Burke DS: Two antigenically distinct subtypes of human immunodeficiency virus type 1: Viral genotype predicts neutralization serotype. J Infect Dis 1994;169:48-54.
12. Nyambi PN, Nkengasong J, Peeters M, Simon F, Eberle J, Janssens W, Fransen K, Willems B, Vereecken K, Heyndrickx L, Piot P, van der Groen G: Reduced capacity for antibodies from patients infected with HIV-1 group O to neutralize primary isolates of HIV-1 group M viruses. J Infect Dis 1995;172:1228-1237.
13. Moore JP, Cao YZ, Leu J, Qin JM, Korber B, Ho DD: Inter- and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 1996;70:427-444.
14. Kostrikis LG, Cao YZ, Ngai H, Moore JP, Ho DD: Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: Lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol 1996;70:445-458.
15. Montefiori DC, Pantaleo G, Fink LM, Zhou JT, Zhou JY, Bilska M, Miralles GD, Fauci AS: Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis 1996;173:60-67.
16. Cao Y, Limo Q, Zhang L, Safrit J, Ho DD: Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995;332:201-208.
17. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, Reefer MC, McElrath MJ, Walker MC, Wagner KF, McNeil JG, McCutchan FE, Burke DS: Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 1996;173:340-348.
18. Sawyer LSW, Wrin MT, Crawford-Miksza L, Potts B, Wu Y, Weber PA, Alfonso RD, Hanson CV: Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J Virol 1994;68: 1342-1349.
19. Wrin T, Crawford L, Sawyer L, Weber P, Sheppard HW, Hanson CV: Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr 1994;7:211-219.
20. Rubsamen-Waigmann H, Von Briesen H, Holmes H, Björndal Å, Korber B, Esser R: Standard conditions of virus isolation reveal biologic variability of HIV type 1 in different regions of the world: AIDS Res Hum Retroviruses 1994;10:1401-1408.
21. Yu X-F, Wang Z, Beyrer C, Celentano DD, Khamboonruang C, Allen E, Nelson K: Phenotypic and genotypic characteristics of human immunodeficiency virus type 1 from patients with AIDS in northern Thailand. J Virol 1995;69:4649-4655.
22. Delwart EL, Shpaer EG, Louwagie J, McCutchan FE, Grez M, Rubsamen-Waigmann H, Mullins JI: Genetic relationships determined by a DNA heteroduplex mobility assay: Analysis of HIV-env genes. Science 1993;262:1257-1261.
23. Artenstein AW, VanCott TC, Mascola JR, Carr JK, Hegerich PA, Gaywee J, Sanders-Buell E, Robb ML, Dayhoff DE, Thitivichianlert S, Nitayaphan S, McNeil JG, Birx DL, Michael RA, Burke DS, McCutchan FE: Dual infection with human immunodeficiency virus type 1 of distinct envelope subtypes in humans. J Infect Dis 1995;171:805-810.
24. Vujcic LK, Quinnan GV Jr: Preparation and characterization of human HIV type 1 neutralizing reference sera. AIDS Res Hum Retroviruses 1995;11:783-788.
25. Moore JP, McCutchan FE, Poon S-W, Mascola J, Liu J, Cao Y, Ho DD: Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol 1994;68:8350-8364.
26. VanCott TC, Bethke FR, Artenstein AW, et al.: Serotyping international HIV-1 isolates by V3 peptides and whole gp160 proteins using BIAcore. Methods: A Companion to Methods Enzymol 1994;6:188-198.
27. VanCott TC, Veit SCD, Kalyanaraman V, Earl P, Birx DL: Characterization of a soluble, oligomeric HIV-1 gp160 protein as a potential immunogen. J Immunol Methods 1995;183:103-117.
28. Mascola JR, Burke DS: Antigen Detection in Neutralization Assays: High Levels of Interfering Anti-p24 Antibodies in Some Plasma (Letter). AIDS Res Hum Retroviruses 1993;9:1173-1174.
29. National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health. Bethesda, MD: Spouge ID-50 software, Version 2.0. 1993.
30. Robertson DL, Sharp PM, McCutchan FE, Hahn BH: Recombination in HIV-1. Nature (London) 1995;374:124-126.
31. Wrin T, Loh TP, Vennari JC, Schuitemaker H, Nunberg JH: Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccinee sera. J Virol 1995;69:39-48.
32. Moore JP, Cao Y, Qing L, Sattentau QJ, Pyati J, Koduri R, Robinson J, Barbas CF III, Burton DR, Ho DD: Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995;69:101-109.
33. Sattentau QJ, Moore JP: Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med 1995;182:185-196.
34. VanCott TC, Polonis VR, Loomis LD, Michael NL, Nara PL, Birx DL: Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res Hum Retroviruses 1995;11:1379-1391.
35. VanCott TC, Bethke FR, Burke DS, Redfield RR, Birx DL: Lack of induction of antibodies specific for conserved discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J Immol 1995;155:4100-4110.
36. McCutchan FE, Artenstein AW, Sanders-Buell E, Salminen MO, Carr JK, Mascola JR, Yu XF, Nelson KE, Khamboonruang C, Schmitt D, Kieny MP, McNeil JG, Burke DS: Diversity of the envelope glycoprotein among human immunodeficiency virus type 1 isolates of clade E from Asia and Africa. J Virol 1996;70:3331-3338.
37. Murphy E, Korber B, Georges-Courbot M-C, You B, Pinter A, Cook D, Kieny M-P, Georges A, Mathiot C, Barre-Sinoussi F, Girard M: Diversity of V3 region sequences of human immunodeficiency viruses type 1 from the Central African Republic. AIDS Res Hum Retroviruses 1993;9:997-1006.
38. Burton DR, Pyati J, Koduri R, Sharpe SJ, Thornton GB, Parren PWHI, Sawyer LSW, Hendry RM, Dunlop N, Nara P, Lamacchia M, Garratty E, Stiehm ER, Bryson YJ, Cao Y, Moore JP, Ho DD, Barbas CF III: Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994; 266:1024-1027.
39. Conley AJ, Gorny MK, Kessler JA II, Boots LJ, Ossorio-Castro M, Koenig S, Lineberger DW, Emini EA, Williams C, Zolla-Pazner S: Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol 1994;68:6994-7000.
40. Corny MK, Moore JP, Conley AJ, Karwowska S, Sodroski J, Williams C, Burda S, Boots LJ, Zolla-Pazner S: Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol 1994;68:8312-8320.
41. D'Souza MP, Milman G, Bradac JA, McPhee D, Hanson CV, Hendry RM, Corcoran T, Stott J, Fung M, Hanson C, Laman J, Mascola J, Rasheed S, Richman D, Schuitemaker H, Thiriart C, Wainberg M, Weber J, Beddows S, Tilley S, Robinson J, Zolla-Pazner S, Katinger H: Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies. AIDS 1995;9:867-874.
42. Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, Allaway GP, Katinger H, Barbas CF III, Burton DR, Ho DD, Moore JP: Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995;69:6609-6617.
43. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H: Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996;70:1100-1108.